Impact of intestinal glucuronidation on the pharmacokinetics of raloxifene

Drug Metabolism and Disposition

Volumn 39, Issue 9, 2011, Pages 1495-1502

  Kosaka, Keigo ^a   Sakai, Norifumi ^b   Endo, Yuya ^b   Fukuhara, Yuga ^a   Tsuda Tsukimoto, Minoru ^a   Ohtsuka, Tatsuyuki ^a   Kino, Ichiro ^a   Tanimoto, Tomohiko ^a   Takeba, Naomi ^a   Takahashi, Masakatsu ^a   Kume, Toshiyuki ^a  

^a Medicinal Chemistry Laboratory   (Japan)

^b LSI MEDIENCE CORPORATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHANIN A; BIOCHANIN A GLUCURONIDE; DRUG METABOLITE; GEMFIBROZIL; GEMFIBROZIL GLUCURONIDE; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A; MULTIDRUG RESISTANCE PROTEIN 2; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID BETA D GLUCURONIDE; RALOXIFENE; RALOXIFENE GLUCURONIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXCRETION; DRUG GLUCURONIDATION; DRUG STRUCTURE; EISAI HYPERBILIRUBINEMIC RAT; ENZYME SUBSTRATE COMPLEX; FIRST PASS EFFECT; GUNN RAT; HAPLORHINI; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; SPECIES DIFFERENCE; SPRAGUE DAWLEY RAT; STRAIN DIFFERENCE; SYSTEMIC CIRCULATION; WILD TYPE; WISTAR RAT;

ANIMALS; BIOLOGICAL AVAILABILITY; DOGS; DRUG DISCOVERY; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; INTESTINES; LIVER; MACACA FASCICULARIS; MALE; MICROSOMES; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; RALOXIFENE; RATS; RATS, GUNN; RATS, SPRAGUE-DAWLEY; RATS, WISTAR;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

EID: 80051959458     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.040030     Document Type: Article

References (38)

1. Conrad S., Viertelhaus A., Orzechowski A., Hoogstraate J., Gjellan K., Schrenk D, and Kauffmann H.M. (2001) Sequencing and tissue distribution of the canine MRP2 gene compared with MRP1 and MDR1. Toxicology 156:81-91. (Pubitemid 32119480)
2. Cubitt H.E., Houston JB, and Galetin A. (2009) Relative importance of intestinal and hepatic glucuronidation- Impact on the prediction of drug clearance. Pharm Res 26:1073-1083.
3. Curtis C.G., Danaher T.M., Hibbert E.A., Morris C.L., Scott A.M., Woolcott BA, and Powell G.M. (1985) The fate of gemfibrozil and its metabolites in the rat. Biochem Soc Trans 13:1190-1191.
4. Dalvie D., Kang P., Zientek M., Xiang C., Zhou S, and Obach R.S. (2008) Effect of intestinal glucuronidation in limiting hepatic exposure and bioactivation of raloxifene in humans and rats. Chem Res Toxicol 21:2260-2271.
5. Davies B and Morris T. (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095. (Pubitemid 23211439)
6. Deguchi T., Watanabe N., Kurihara A., Igeta K., Ikenaga H., Fusegawa K., Suzuki N., Murata S., Hirouchi M., Furuta Y., et al. (2011) Human pharmacokinetic prediction of UDP- Glucuronosyltransferase substrates with an animal scale- Glucuronosyltransferase substrates with an animal scaleUp approach. Drug Metab Dispos 39:820-829.
7. Galetin A and Houston J.B. (2006) Intestinal and hepatic metabolic activity of five cytochrome P 450 enzymes: impact on prediction of first- Pass metabolism. J Pharmacol Exp Ther 318:1220-1229. (Pubitemid 44268329)
8. Gertz M., Harrison A., Houston JB, and Galetin A. (2010) Prediction of human intestinal first- Pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. Drug Metab Dispos 38:1147-1158.
9. Iwatsubo T., Hirota N., Ooie T., Suzuki H, and Sugiyama Y. (1996) Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics. Biopharm Drug Dispos 17:273-310. (Pubitemid 26176731)
10. Jeong E.J., Lin H, and Hu M. (2004) Disposition mechanisms of raloxifene in the human intestinal Caco- 2 model. J Pharmacol Exp Ther 310:376-385. (Pubitemid 38812733)
11. Jeong E.J., Liu Y., Lin H, and Hu M. (2005) Species- And disposition model- And disposition modelDependent metabolism of raloxifene in gut and liver: role of UGT1A10. Drug Metab Dispos 33:785-794. (Pubitemid 40686632)
12. Jia X., Chen J., Lin H, and Hu M. (2004) Disposition of flavonoids via enteric recycling: enzyme- Transporter coupling affects metabolism of biochanin A and formononetin and excretion of their phase II conjugates. J Pharmacol Exp Ther 310:1103-1113. (Pubitemid 39108932)
13. Kadono K., Akabane T., Tabata K., Gato K., Terashita S, and Teramura T. (2010) Quantitative prediction of intestinal metabolism in humans from a simplified intestinal availability model and empirical scaling factor. Drug Metab Dispos 38:1230-1237.
14. Kemp D.C., Fan PW, and Stevens J.C. (2002) Characterization of raloxifene glucuronidation in vitro: Contribution of intestinal metabolism to presystemic clearance. Drug Metab Dispos 30:694-700. (Pubitemid 34579104)
15. Kilford P.J., Stringer R., Sohal B., Houston JB, and Galetin A. (2009) Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP- Glucuronosyltransferase cofactors in alamethicin- Glucuronosyltransferase cofactors in alamethicinActivated human liver microsomes. Drug Metab Dispos 37:82-89.
16. Kim M.S., Liu D.Q., Strauss J.R., Capodanno I., Yao Z., Fenyk-Melody J.E., Franklin RB, and Vincent S.H. (2003) Metabolism and disposition of gemfibrozil in Wistar and multidrug resistance- Associated protein 2- Associated protein 2Deficient TR- rats. Xenobiotica 33:1027-1042. (Pubitemid 37346685)
17. Lewinsky R.H., Smith PA, and Mackenzie P.I. (2005) Glucuronidation of bioflavonoids by human UGT1A10: structure- Function relationships. Xenobiotica 35:117-129. (Pubitemid 40769764)
18. Lin JH and Wong B.K. (2002) Complexities of glucuronidation affecting in vitro Glucuronosyltransferase 2B7 activity by albumin: implications for in vitroIn vivo extrapolation. Curr Drug Metab 3:623-646.
19. Lindstrom T.D., Whitaker NG, and Whitaker G.W. (1984) Disposition and metabolism of a new benzothiophene antiestrogen in rats, dogs and monkeys. Xenobiotica 14:841-847. (Pubitemid 15180639)
20. Luttringer O., Theil F.P., Poulin P., Schmitt-Hoffmann A.H., Guentert TW, and Lavé T. (2003) Physiologically based pharmacokinetic (PBPK) modeling of disposition of epiroprim in humans. J Pharm Sci 92:1990-2007. (Pubitemid 37175630)
21. Miners J.O., Mackenzie PI, and Knights K.M. (2010) The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential. Drug Metab Rev 42:196-208.
22. Mizuma T. (2009) Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: a study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10. Int J Pharm 378:140-141.
23. Mottino A.D., Hoffman T., Jennes L, and Vore M. (2000) Expression and localization of multidrug resistant protein Mrp2 in rat small intestine. J Pharmacol Exp Ther 293:717-723. (Pubitemid 30417835)
24. Nies A.T., Schwab M, and Keppler D. (2008) Interplay of conjugating enzymes with OATP uptake transporters and ABCC/MRP efflux pumps in the elimination of drugs. Expert Opin Drug Metab Toxicol 4:545-568. (Pubitemid 351890738)
25. Ohno S and Nakajin S. (2009) Determination of mRNA expression of human UDP- Glucuronosyltransferases and application for localization in various human tissues by real- Glucuronosyltransferases and application for localization in various human tissues by realTime reverse transcriptase- Glucuronosyltransferases and application for localization in various human tissues by realTime reverse transcriptasePolymerase chain reaction. Drug Metab Dispos 37:32-40.
26. Pang K.S., Maeng H, and Fan (2009) Interplay of transporters and enzymes in drug and metabolite processing. Mol Pharm 6:1734-1755.
27. Perloff M.D., Von Moltke LL, and Greenblatt D.J. (2004) Ritonavir and dexamethasone induce expression of CYP3A and P- Glycoprotein in rats. Xenobiotica 34:133-150. (Pubitemid 38299715)
28. Ritter J.K. (2007) Intestinal UGTs as potential modifiers of pharmacokinetics and biological responses to drugs and xenobiotics. Expert Opin Drug Metab Toxicol 3:93-107.
29. Rowland A., Gaganis P., Elliot D.J., Mackenzie P.I., Knights KM, and Miners J.O. (2007) Binding of inhibitory fatty acids is responsible for the enhancement of UDP- Glucuronosyltransferase 2B7 activity by albumin: implications for in vitro-in vivo extrapolation. J Pharmacol Exp Ther 321:137-147. (Pubitemid 46456976)
30. Rowland A., Knights K.M., Mackenzie PI, and Miners J.O. (2008) The "albumin effect" and drug glucuronidation: bovine serum albumin and fatty acid- Free human serum albumin enhance the glucuronidation of UDP- Free human serum albumin enhance the glucuronidation of UDPGlucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities. Drug Metab Dispos 36:1056-1062. (Pubitemid 351717462)
31. - and Wistar rat liver preparations. Drug Metab Dispos 38:769-780.
32. Takekuma Y., Kakiuchi H., Yamazaki K., Miyauchi S., Kikukawa T., Kamo N., Ganapathy V, and Sugawara M.(2007) Difference between pharmacokinetics of mycophenolic acid (MPA) in rats and that in humans is caused by different affinities of MRP2 to a glucuronized form. J Pharm Pharm Sci 10:71-85. (Pubitemid 46695408)
33. Von Moltke L.L., Greenblatt D.J., Harmatz JS, and Shader R.I. (1993) Alprazolam metabolism in vitro: Studies of human, monkey, mouse, and rat liver microsomes. Pharmacology 47:268-276. (Pubitemid 23256327)
34. Wang S.W., Kulkarni K.H., Tang L., Wang J.R., Yin T., Daidoji T., Yokota H, and Hu M. (2009) Disposition of flavonoids via enteric recycling: UDP- Glucuronosyltransferase (UGT) 1As deficiency in Gunn rats is compensated by increases in UGT2Bs activities. J Pharmacol Exp Ther 329:1023-1031.
35. Xu H., Kulkarni K.H., Singh R., Yang Z., Wang S.W., Tam VH, and Hu M. (2009) Disposition of naringenin via glucuronidation pathway is affected by compensating efflux transporters of hydrophilic glucuronides. Mol Pharm 6:1703-1715.
36. Yang J., Jamei M., Yeo K.R., Tucker GT, and Rostami-Hodjegan A. (2007) Prediction of intestinal first- Pass drug metabolism. Curr Drug Metab 8:676-684. (Pubitemid 47578116)
37. Zhang L., Zuo Z, and Lin G. (2007) Intestinal and hepatic glucuronidation of flavonoids. Mol Pharm 4:833-845.
38. Zhou S.F., Tingle M.D., Kestell P, and Paxton J.W. (2002) Species differences in the metabolism of the antitumour agent 5,6- Dimethylxanthenone-4- Dimethylxanthenone4Acetic acid in vitro: implications for prediction of metabolic interactions in vivo. Xenobiotica 32:87-107. (Pubitemid 34155217)